Since NF-κB is involved in various cancer-related processes, including inflammation, tumor progression, and chemoresistance, the specific inhibition of this pathway by CalebinA highlights its potential as a molecular-targeted therapy. The gene discussed is NFKB1; the disease is neoplasm.